---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-268939"
form_type: "8-K"
ticker: "VOR"
cik: "0001817229"
company_name: "Vor Biopharma Inc."
filed_at: "2023-11-02T23:59:59+00:00"
generated_at: "2026-06-09T00:51:47.716117+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Vor Bio: ASH presentations show trem-cel engraftment; CD33CART 40% complete remission at highest dose

## Summary
- VBP101 (trem-cel) abstract accepted for oral at ASH; shows robust neutrophil engraftment and hematologic protection from Mylotarg.
- CD33CART Phase 1: 2/5 (40%) evaluable patients at DL4 achieved complete remission; 4/19 had CRS ≥ Grade 3.
- VCAR33 ALLO uses same CAR-T construct as CD33CART but from healthy donors; VBP301 trial-in-progress poster at ASH.
- Preclinical collaboration with Janssen: CD33-deleted allografts synergistic with JNJ-67571244, reducing cytokines.
- Single-cell analysis of 28 AML patients (most comprehensive to date) accepted for oral presentation at ASH.

## SEC filing metadata
- accession: 0001193125-23-268939
- form_type: 8-K
- ticker: VOR
- cik: 0001817229
- company_name: Vor Biopharma Inc.
- filed_at: 2023-11-02T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1817229/000119312523268939/0001193125-23-268939-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1817229/000119312523268939/d554165d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-268939
- JSON: https://secwatch.observer/filing/0001193125-23-268939.json
- Plain text: https://secwatch.observer/filing/0001193125-23-268939.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.